RAC 4.32% $1.55 race oncology ltd

Industry news, page-774

  1. 2,710 Posts.
    lightbulb Created with Sketch. 2824
    I guess they don’t see value on attracting investors or progressing trials that can make or break.

    playing devils advocate can’t we have the best of both worlds market and progress trials?

    Otherwise isn’t it just perpetuating the volatility in biotech when rapid SP movements rather than consistent
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.